Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
144 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Oropharyngeal Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2016, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape. Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types, HPV-positive, which are related to human papillomavirus infection, and HPV-negative cancers, which are usually linked to alcohol or tobacco use. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Oropharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.Oropharyngeal Cancer. Oropharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Oropharyngeal Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Oropharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Oropharyngeal Cancer Overview 8 Therapeutics Development 9 Pipeline Products for Oropharyngeal Cancer - Overview 9 Pipeline Products for Oropharyngeal Cancer - Comparative Analysis 10 Oropharyngeal Cancer - Therapeutics under Development by Companies 11 Oropharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes 12 Oropharyngeal Cancer - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Oropharyngeal Cancer - Products under Development by Companies 16 Oropharyngeal Cancer - Products under Investigation by Universities/Institutes 17 Oropharyngeal Cancer - Companies Involved in Therapeutics Development 18 Advaxis, Inc. 18 AstraZeneca Plc 19 Cell Medica Limited 20 Genticel S.A. 21 Immunovaccine Inc 22 ISA Pharmaceuticals B.V. 23 Kolltan Pharmaceuticals, Inc. 24 Merck & Co., Inc. 25 Novartis AG 26 PNP Therapeutics, Inc. 27 Tessa Therapeutics Pte Ltd 28 VLPbio 29 Oropharyngeal Cancer - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 alpelisib - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 axalimogene filolisbac - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 CMD-004 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 DPXE-7 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 ganetespib - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 gedeptin - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 GTL-001 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 HNVax - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 ISA-101 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 KTN-3379 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 nimotuzumab - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 olaparib - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 pembrolizumab - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 PGV-001 - Drug Profile 135 Product Description 135 Mechanism Of Action 135 R&D Progress 135 TT-12 - Drug Profile 136 Product Description 136 Mechanism Of Action 136 R&D Progress 136 Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile 137 Product Description 137 Mechanism Of Action 137 R&D Progress 137 Oropharyngeal Cancer - Dormant Projects 138 Oropharyngeal Cancer - Product Development Milestones 139 Featured News & Press Releases 139 Aug 11, 2016: Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage 139 Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company's Lm Technology™ Platform 139 Sep 14, 2015: FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac in HPV-Associated Head and Neck Cancer 141 Jun 09, 2015: U.S. FDA approves IND application for TT12 HP-VST to begin Phase I trial involving Adoptive T cell therapy on Oropharyngeal Cancer and Cervical Cancer 142 Appendix 143 Methodology 143 Coverage 143 Secondary Research 143 Primary Research 143 Expert Panel Validation 143 Contact Us 143 Disclaimer 144
List of Tables Number of Products under Development for Oropharyngeal Cancer, H2 2016 9 Number of Products under Development for Oropharyngeal Cancer - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Oropharyngeal Cancer - Pipeline by Advaxis, Inc., H2 2016 18 Oropharyngeal Cancer - Pipeline by AstraZeneca Plc, H2 2016 19 Oropharyngeal Cancer - Pipeline by Cell Medica Limited, H2 2016 20 Oropharyngeal Cancer - Pipeline by Genticel S.A., H2 2016 21 Oropharyngeal Cancer - Pipeline by Immunovaccine Inc, H2 2016 22 Oropharyngeal Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2016 23 Oropharyngeal Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 24 Oropharyngeal Cancer - Pipeline by Merck & Co., Inc., H2 2016 25 Oropharyngeal Cancer - Pipeline by Novartis AG, H2 2016 26 Oropharyngeal Cancer - Pipeline by PNP Therapeutics, Inc., H2 2016 27 Oropharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 28 Oropharyngeal Cancer - Pipeline by VLPbio, H2 2016 29 Assessment by Monotherapy Products, H2 2016 30 Number of Products by Stage and Target, H2 2016 32 Number of Products by Stage and Mechanism of Action, H2 2016 34 Number of Products by Stage and Route of Administration, H2 2016 36 Number of Products by Stage and Molecule Type, H2 2016 38 Oropharyngeal Cancer - Dormant Projects, H2 2016 138
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
